X-Feed Billboard (International)

The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.

GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.

F&G: 68
5.846,75 S&P · 20,53 Vola-Index · 111.174,41 BTC · 1,13129 EURUSD
System-State: Number of processed items 71.121 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
GlobeNewsWire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
State: 23.05.2025 | 6AM
Thu, 22.05.2025       Wisekey

WISeKey Updates on the Negotiations to Acquire 100% of IC'ALPS

Thu, 22.05.2025       Mare Nostrum

MARE NOSTRUM
Chiffre d’affaires solide au 1er trimestre 2025 de 28 M€
Finalisation des projets de plan de continuation

Thu, 22.05.2025       CoinShares International

Thursday, 22 May 2025 | SAINT HELIER, Jersey - CoinShares International Limited ("CoinShares" or the "Company") (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF), a global investment firm specializing in digital assets, today announced that it has agreed to enter a block transaction with a shareholder to acquire 200,000 ordinary shares in the capital of the Company.

CoinShares International
Thu, 22.05.2025       Octopus AIM VCT

Thu, 22.05.2025       Tarkett

Upon the recommendation of the ad hoc Committee, the Supervisory Board of Tarkett reiterates a favourable reasoned opinion on the fairness of the public buy-out Offer followed by a squeeze-out.

Thu, 22.05.2025       Trivago

Thu, 22.05.2025       Elis

Combined shareholders’ meeting of May 22, 2025

Thu, 22.05.2025       Courtois

****
Toulouse, le 22 mai 2025

Thu, 22.05.2025       Valeo

Thu, 22.05.2025       Nexity

NEXITY
Société anonyme au capital de 280.648.620 euros
Siège social : 67 rue Arago – 93400 SAINT-OUEN-SUR-SEINE
444 346 795 RCS BOBIGNY

Thu, 22.05.2025       Coface

AM Best affirms ratings of Coface’s main operating subsidiaries

Thu, 22.05.2025       Groupe Guillin

Thu, 22.05.2025       Freddie Mac

MCLEAN, Va., May 22, 2025 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.86%.

Thu, 22.05.2025       Akva Group

The annual general meeting of AKVA group ASA was held today, 22 May 2025. The minutes from the meeting are attached to this notice and will be made available on the company's website, https://www.akvagroup.com/investors/general-meeting/

Thu, 22.05.2025       Toll Brothers

Exclusive luxury community includes access to expansive amenities in sought-after Lake Nona
Exclusive luxury community includes access to expansive amenities in sought-after Lake Nona
Thu, 22.05.2025       Euronext

Euronext announces the success of its offering of bonds due 2032 convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) for a nominal amount of €425 million

Thu, 22.05.2025       Shell

Thu, 22.05.2025       Transgene

24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050
in resected locally advanced head and neck cancer selected for rapid oral presentation
at ASCO on June 1st, 2025

Thu, 22.05.2025       Roche Holding

Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR), a potentially blinding condition that affects almost 10 million people in the US and more than 100 million people globally.1,2 It is the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with just one refill every nine months.3,4 Susvimo is now available to US retina specialists and their patients with DR who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.

Thu, 22.05.2025       Sildarvinnslan


Helstu niðurstöður úr fjárhagsuppgjöri tímabilsins 

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.